Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 13/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23725248 | 0.90 | SSTR4 (0.36) | IRAK4CD274PDCD1PDCD1LG2POLB | |
| SCHEMBL23726152 | 0.85 | KCNA5 (0.37) | CD274PDCD1PDCD1LG2POLBMAPK1 | |
| SCHEMBL23725774 | 0.82 | CD274 (0.43) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL29984044 | 0.79 | CD274 (0.37) | IRAK4CD274PDCD1PDCD1LG2MAPK1 | |
| SCHEMBL23725822 | 0.78 | CD274 (0.54) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL29983461 | 0.77 | CD274 (0.48) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL27080849 | 0.77 | CD274 (0.48) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23726118 | 0.77 | CD274 (0.56) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL31223974 | 0.76 | IRAK4 (0.34) | IRAK4CD274PDCD1PDCD1LG2 | |
| SCHEMBL30836742 | 0.76 | CD274 (0.46) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | IRAK4 1378/4885CD274 75/4885PDCD1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.